Related Experiment Videos
Circadian patterns of plasma cortisol, 17-hydroxyprogesterone, and testosterone in congenital adrenal hyperplasia
Insights
Monitoring congenital adrenal hyperplasia (21-hydroxylase deficiency) requires more than single 17-hydroxyprogesterone measurements. Fluctuating levels indicate treatment quality is best assessed by integrated 24-hour hormone profiles, not isolated values.
Area of Science:
- Pediatric Endocrinology
- Metabolic Disorders
- Hormone Therapy
Background:
- Congenital adrenal hyperplasia (CAH), specifically 21-hydroxylase deficiency, is a group of inherited metabolic disorders.
- Effective management of CAH relies on precise monitoring of hormone levels to ensure adequate treatment and prevent complications.
Purpose of the Study:
- To evaluate the utility of various hormone level measurements in assessing treatment quality for children with non-salt-losing CAH.
- To determine the most reliable biomarker for monitoring therapeutic efficacy in pediatric CAH patients.
Main Methods:
- Blood samples were collected every 90 minutes over 24 hours from 11 children (ages 2-17) with CAH.
- Measured hormones included 17-hydroxyprogesterone, testosterone, and cortisol.
- Analyzed 24-hour urine samples for 17-ketosteroids and pregnanetriol levels.
- Measurements were taken during different treatment regimens and after treatment interruption.
Main Results:
- Cortisol levels exhibited rapid, high fluctuations post-corticosteroid administration.
- Testosterone levels varied significantly but generally remained within normal ranges, indicating limited value as a control parameter.
- 17-hydroxyprogesterone levels showed extreme fluctuations, with high peaks in untreated patients and significant post-midnight rises even with standard treatment.
- A strong correlation was observed between 24-hour pregnanetriol excretion and integrated 17-hydroxyprogesterone levels.
- A steep decline in 17-hydroxyprogesterone was noted after the morning hydrocortisone dose.
Conclusions:
- Single measurements of 17-hydroxyprogesterone are insufficient for accurately assessing treatment quality in CAH.
- Integrated 24-hour hormone profiles, particularly pregnanetriol excretion, provide a more comprehensive understanding of treatment effectiveness.
- Testosterone is not a reliable indicator for monitoring CAH treatment quality.
Abstract:
In 11 children aged between 2 and 17 years with (nonsalt-losing) congenital adrenal hyperplasia (21-hydroxylase deficiency) blood was drawn at 90-minute intervals during a 24-hour period and levels of 17-hydroxyprogesterone, testosterone, and cortisol were measured. Levels of 17-ketosteroids and pregnanetriol were measured too in 24-hour urine samples. These measurements were taken under different regimens of treatment and after interruption of treatment. Cortisol level rose and fell rapidly after administered corticosteroid, and reached unphysiologically high levels. Testosterone levels showed pronounced variations but stayed in the normal range for most of the time even in untreated patients; thus testosterone provides a poor control parameter. Levels of 17-hydroxyprogesterone showed extreme fluctuations and very high peak levels in untreated patients; standard treatment with two or three daily doses of corticosteroids did not prevent a pronounced rise in its level after midnight. After the first morning dose of hydrocortisone a very steep fall was observed. The 24-hour pregnanetriol excretion correlated well with the corresponding total integrated 17-hydroxyprogesterone area. It is concluded that single 17-hydroxyprogesterone values are unlikely to give adequate information about the quality of treatment.